```json
{
"content": [
{
"type": "paragraph",
"content": "The Eye Vitamins market outlook remains highly attractive as aging populations, rising screen exposure, and growing self-care culture lift demand for AREDS-2-based formulations and blue-light supplements. Competitive intensity is moderate but rising fast: incumbent OTC pharma and vitamin leaders defend shelf space while VC-backed direct-to-consumer brands accelerate spend on digital acquisition, squeezing margins above 15% CAGR. Over the next five years, we expect the category to outpace broader VMS by 5–6 pp, driven by Asia–Pacific expansion and prescription-to-OTC switches."
},
{
"type": "paragraph",
content: "The innovation landscape is shifting from single-antioxidant pills toward clinically validated, condition-specific SKUs combining lutein, zeaxanthin, omega-3s, and even probiotics. Supply is broadly secure, yet patented lutein supply is concentrated in three players; any crop disruption would cascade into a 6–8% ingredient cost spike. Key risks include tighter FTC/EFSA substantiation rules, potential AREDS guideline revisions, and a consumer shift toward food-based eye health, which could erode supplement penetration. Overall, the reward-to-risk profile is favorable for players able to invest in clinical evidence, protect supply chains, and localize brand narratives."
}
]
}
```
